Free Delivery Over $100
|
|
|||
|
||||
Overview"Almost a century ago Paul Ehrlich introduced the ""magic bullet"" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology." Full Product DetailsAuthor: Marie-Luise Sautter-Bihl , Heiner Bihl , Michael WannenmacherPublisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG Imprint: Springer-Verlag Berlin and Heidelberg GmbH & Co. K Edition: Softcover reprint of the original 1st ed. 1996 Volume: 141 Dimensions: Width: 15.50cm , Height: 1.10cm , Length: 23.50cm Weight: 0.330kg ISBN: 9783642799549ISBN 10: 364279954 Pages: 198 Publication Date: 14 December 2011 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of ContentsReviewsa timely and deliberately provocative new impetus to this long overdue discussion of promising, selective cancer treatment. Jnl. of the National Cancer Institute Author InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
